Hangzhou Shield Biotech

Hangzhou Shield Biotech is a clinical-stage biotechnology company based in China, specializing in the development of mRNA-based vaccines and therapeutics. The company leverages a proprietary mRNA synthesis and lipid nanoparticle (LNP) delivery platform to address significant unmet needs in infectious diseases and oncology. Its lead candidate is an mRNA-based rabies vaccine, which has successfully entered clinical trials, marking it as one of the first of its kind in the region. Beyond rabies, Shield Biotech is advancing a diverse pipeline that includes candidates for COVID-19, seasonal influenza, and various solid tumors. The company maintains integrated research, development, and manufacturing capabilities in Hangzhou to support its end-to-end mRNA production needs. Shield Biotech is backed by prominent venture capital firms, including Qiming Venture Partners and Sherpa Healthcare Partners.